SCLX (Scilex Holding Co) Total Stockholders Equity: $-249.22 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCLX Scilex Holding Co SCLX
56 GF Score
Price $6.80
GF Value $5.82
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Scilex Holding Co Total Stockholders Equity?

Scilex Holding Co SCLX +0.74% 56 Total Stockholders Equity is $-249.22 Mil as of Mar. 2026. GuruFocus rates SCLX with a GF Score™ of 56/100 and a GF Value™ of $5.82 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Scilex Holding Co's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-249.22 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Scilex Holding Co's Book Value per Share for the quarter that ended in Mar. 2026 was $-35.44. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Scilex Holding Co's Debt-to-Equity for the quarter that ended in Mar. 2026 was -0.39.

Scilex Holding Co  (NAS:SCLX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Scilex Holding Co's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-249.219-0)/7.033
=-35.44

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Scilex Holding Co's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(85.273 + 12.686) / -249.219
=-0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scilex Holding Co Total Stockholders Equity Related Terms

Scilex Holding Co Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Scilex Holding Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scilex Holding Co Total Stockholders Equity Chart

Scilex Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial -223.88 36.24 -172.94 -192.64 -207.78

Scilex Holding Co Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -211.48 -248.99 -176.94 -207.78 -249.22
SCLX
56GF Score
Scilex Holding Co SCLX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-249.22 Mil mean?
Scilex Holding Co (SCLX) has a Total Stockholders Equity of $-249.22 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Scilex Holding Co and its competitors.
Is Scilex Holding Co's Total Stockholders Equity too high?
Scilex Holding Co's current Total Stockholders Equity is $-249.22 Mil. Overall, Scilex Holding Co has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's Total Stockholders Equity compare to MIRA and NSRX?
Scilex Holding Co's Total Stockholders Equity of $-249.22 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Scilex Holding Co and its competitors. Scilex Holding Co's current Total Stockholders Equity is $-249.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (SCLX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.82, compared to a current price of $6.80 — trading 16.8% above its estimated fair value. The current Total Stockholders Equity is $-249.22 Mil. Scilex Holding Co's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Scilex Holding Co (SCLX), the current Total Stockholders Equity is $-249.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scilex Holding Co (SCLX) Overvalued in 2026?

Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued. The current stock price of $6.80 is trading 16.8% above its estimated GF Value™ of $5.82. GuruFocus considers Scilex Holding Co to be Modestly Overvalued.

Key valuation signals for SCLX:

  • Total Stockholders Equity: $-249.22 Mil
  • GF Value™: $5.82 vs. price of $6.80 (16.8% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scilex Holding Co Business Description

Other Exchanges D8B0:Germany
Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
56GF Score

Get the complete analysis for SCLX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.80
Price
$5.82
GF Value